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SUMMARY 
Background. Severe asthma (SA) is a heterogeneous disease with variability in 
clinical history, physiologic abnormalities, pattern of airway inflammation and 
responses to therapy, and often associated with comorbidities that can influence 
these characteristics. The WHO document has classified SA in two principal 
groups: difficult-to-treat (DT)-SA and treatment-resistant (TR)-SA, in which the 
poor control of asthma is due respectively to other factors than asthma, in 
particular comorbidities, and poor sentitivity to asthma treatment. Aims of this 
study are: 1) to characterize and compare demographic, functional and 
inflammatory parameters and the level of control of the patients with DT-SA 
and TR-SA, 2) to evaluate the prevalence of comorbidities and their combined 
effect on asthma control, asthma related quality of life, lung function and airway 
inflammation in severe asthmatics, 3) to adapt the treatment to the different 
asthma phenotypes and to evaluate the effect on indices of control, quality of 
life, pulmonary function and number of exacerbations. 
Patients and methods. We studied 72 patients with SA. We collected for each 
patient demographic data, smoking habit, asthma history, assessment of 
comorbidities. Pulmonary function, inflammatory biomarkers, upper airway 
disease evaluation, control of asthma and quality of life were carefully assessed. 
49 patients entered in a longitudinal phase: 15 obese patients were sent to 
obesity center for weight loss program, 23 patients with chronic rhino-sinusitis 
(CRS) were sent to ENT to optimize the treatment of upper airway disease and 
11 patients were randomized to increase inhaled corticosteroid to 2000 mcg/day 
of fluticasone propionate. These patient were assessed after one years to 
evaluate the effect on airway inflammation, pulmonary function, asthma control, 
asthma related quality of life and exacerbations. 
Results. No significant differences between TR-SA and DT-SA were observed 
for demographic, clinical, functional and biological features of the disease. We 
observed a high prevalence of CRS with nasal polyps (CRSwNP), obesity and 
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gastro-esophageal reflux (GER), respectively 34.7%, 34.7% and 40.3%. 
Asthmatics with CRSwNP had lower lung function and higher sputum 
eosinophilia; obese asthmatics had worse asthma control and quality of life and 
a trend to have lower sputum eosinophilia; asthmatics with GER showed worse 
quality of life. In multivariate analysis, obesity was the only independent factor 
associated with poor control (OR: 4.9), while CRSwNP and duration of asthma 
were the only independent factors associated with airway eosinophilia (OR: 16.2 
and 0.1, respectively). Lower lung function was associated with the male gender 
and the longer duration of asthma (OR: 3.9 and 5.1, respectively) and showed a 
trend for the association with CRSwNP (OR 2.9, p=0.06). In the longitudinal 
phase of our study, despite the small number of patients included in the different 
intervention programs, we observed that the weight loss in obese SA could 
induce an improvement in control of asthma and asthma-related quality of life 
and an effective treatment of CRS in SA could determine a reduction in asthma 
exacerbations. An increase of ICS at 2000 mcg/day of fluticasone propionate 
does not seem to make any benefit in asthma outcomes. 
Conclusions. Our study confirms the high prevalence of coexisting 
comorbidities in SA patients, which are associated with different asthma 
features. In particular, the association between obesity and poor asthma control, 
between CRSwNP and airway eosinophilia and lower lung function, and 
between GER and lower quality of life suggests the importance of the rigorous 
characterization of severe asthmatics for obtaining a better management. The 
weight loss in obese patients can induce an improvement in asthma control and 
asthma-related quality of life and the optimal treatment of CRS can reduce 
asthma exacerbations.  
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INTRODUCTION 
 
Severe asthma (SA) represents a major problem in asthma management. 
Although SA represents no more than 10% of all asthma patients, it is 
responsible for the large majority of direct and indirect costs for asthma in the 
word (1,2). In Italy, it has been calculated that the mean annual asthma-related 
cost of a patient with severe asthma is 3300 euros (sum of the direct medical and 
the indirect costs)  (3). For this reason, a great attention has been done in the last 
few years to a better assessment and management of this limited group of 
patients. 
The recent ERS/ATS document defined SA as “asthma which requires 
treatment with guidelines suggested medications for GINA steps 4-5 (high dose 
inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA) and/or 
leukotriene modifier/theophylline) for the previous year or systemic CS for 
>50% of the previous year, to prevent it from becoming uncontrolled or which 
remains uncontrolled despite this therapy” (4). This definition includes a 
heterogeneous group of patients with a variety of clinical histories, physiologic 
characteristics, types of airway inflammation and responses to therapy, 
suggesting that SA is not an uniform disease but a collection of different 
phenotypes that are categorized as asthma because they meet the criteria for 
diagnosis of asthma but that require different managements. Multiple 
approaches to phenotyping have been proposed, either related to 
clinical/physiologic characteristics, triggering factors and inflammatory 
components (5), or based on large-scale cluster analysis, which utilized together 
many features of asthma. An example of this last analysis is the Severe Asthma 
Research Program (SARP): in this initiative, using predominantly clinical 
characteristics five clusters of asthma were identified (6): three groups of mild, 
moderate and severe early-onset atopic asthma, a more severe late-onset obese 
group and a late-onset very severe and less atopic group. Similarly the Leicester 
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study (7) identified four clusters including a similar early-onset atopic asthma, 
an obese non-eosinophilic asthma, an early-onset symptom predominant asthma 
and a late-onset eosinophilic asthma.   
Although the identification of certain phenotypes may eventually promote 
targeted therapy or help to predict different natural histories, some overlap exists 
between different phenotypes and there are currently no widely accepted 
definitions of specific asthma phenotypes. Furthermore, severe asthma is often 
associated with coexisting conditions, such as rhino-sinusitis, gastro-esophageal 
reflux disease; psychological disturbances, chronic infections and obstructive 
sleep apnea, that can change the asthma phenotype, be part of the same 
pathophysiological process or act as confounding factors in the diagnosis or 
assessment of control of asthma (8). 
An attempt to simplify was carried out some years ago by the World 
Health Organization (WHO), which published a document in which patients 
with severe asthma were divided in 3 groups: untreated severe asthma, difficult-
to-treat severe asthma and treatment-resistant severe asthma (9). Apart the first 
group, the other two groups include patients with poor controlled asthma despite 
high ICS therapy, where the poor asthma control may be due either to a relative 
insensibility to corticosteroid therapy (treatment-resistant SA) and/or to factors 
other than asthma, like poor access to medical treatment, poor adherence to 
medications, environmental exposures, psychosocial issues and comorbidities 
(difficult-to-treat SA). For these reasons, the management of severe asthmatics 
includes a stepwise procedure in which a crucial point is the identification and 
proper treatment of comorbidities that can influence the control of asthma (10).  
Some important comorbidities associated with poor asthma control are 
represented by upper airway diseases (in particular chronic rhino-sinusitis, with 
or without nasal polyps), obesity and gastro-esophageal reflux.  
As for chronic rhino-sinusitis (CRS), more than 50% of patients with 
sinus disease have asthma and 80-90% of adult with asthma have sinus 
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abnormalities on computed tomography (11). In the study of Bresciani et al, 
74% of subjects with steroid-dependent severe asthma had symptoms of rhino-
sinusitis and all had abnormal paranasal sinuses CT scan results (12). In patients 
with CRS associated with asthma, the severity of sinus abnormalities is reported 
to be related to sputum eosinophilia (12,13). CRS with nasal polyposis is often 
associated with a more severe asthma phenotype, often with aspirin intolerance, 
increased lower eosinophilic airway inflammation (14), increased airway 
obstruction and reduced asthma control (15). As for CRS treatment, some 
studies on medical or surgical treatment for CRS had shown improvement in 
bronchial symptoms (16, 17, 18) and lung function (19) and reduction in the 
number of asthma attacks (17) and other studies denied the improvement in lung 
function (16, 20) and symptoms (21). No study was conducted in patients with 
severe asthma.  
Several studies have identified an increased prevalence of asthma among 
obese individuals compared with those of normal weight, although the exact 
reason for the association is not known (23,24,25). Asthma associated with 
obesity is often more difficult to control and less likely to respond to traditional 
asthma therapy (26). The weight loss in obese asthmatics determines 
improvements in asthma control (27). However, studies addressing the role of 
weight loss for severe asthma are limited and improved asthma control in these 
patients has not been consistently demonstrated (28,29). 
Gastro-esophageal reflux (GER) is present in 60–80% of asthmatics (30), 
but clinical trials with anti-reflux therapy generally show little to no effect on 
asthma control (31). 
The prevalence of these comorbidities is particularly high in patients with 
severe asthma, but there are no data on their combined effect on the control of 
asthma, asthma related quality of life, lung function and airway inflammation in 
these patients. 
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This study includes two phases: 
• a first cross-sectional phase, with the aim to characterize and compare the 
clinical, functional and inflammatory profiles in two groups of patients with 
severe asthma (Group A: difficult-to-treat SA; Group B: treatment-resistant 
SA), and to evaluate the prevalence of comorbidities (in particular obesity, 
upper airway diseases and GER) and their influence on airway inflammation, 
pulmonary function, asthma control, asthma-related quality of life and 
exacerbations; 
• a second longitudinal phase, in which 49 patients underwent the following 
therapeutic interventions: 
o 15 obese patients were sent to an obesity center for supervised weight-
loss program (obese group),  
o 23 patients with CRS were sent to ENT clinic to improve the treatment 
of CRS (ENT group); 
o 11 patients with poorly or partially controlled asthma, without CRS or 
obesity and adherent to therapy, that according GINA guideline would 
have to introduce oral corticosteroids, were randomized to step-up the 
inhaled corticosteroids (ICS) therapy to double the maximum 
recommended dose: from 1000 mcg/day to 2000 mcg /day of 
fluticasone propionate (“modification of inhaled asthma treatment 
group”).  
ICS are currently the basis in asthma therapy and in a systematic review, 
action plans in which the ICS dose was at least doubled were associated with 
improved asthma outcomes and reduced health care utilization (32). In a study, 
patients that temporally quadruplet their ICS dose (to average of 2000 mcg/day 
BDP equivalent) after their PEF fell were significantly less likely to require 
OCS (33). 
	  	  
11	  
11	  
The patients that entered in the longitudinal phase of our study were 
reassessed after one year with a complete visit to evaluate the effect on airway 
inflammation, pulmonary function, asthma control, asthma related quality of life 
and exacerbations. 
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PATIENTS AND METHODS 
 
Patients 
We selected from our clinical routine 72 patients with asthma, who met 
the World Health Organization (WHO) definition of severe asthma at the time 
of the enrollment (January 2011-december 2012). All of them satisfied to the 
following criteria: a) diagnosis of asthma at the first examination in our Unit, 
according to the presence of typical symptoms and risk factors, associated with 
variable airway obstruction and/or bronchial hyperresponsiveness; b) a follow-
up observation of one year at least in our Unit, during which adherence to 
therapy was assessed, comorbidities were checked and appropriately treated at 
the best, and pharmacologic treatment was appropriately performed; c) 
persistence, at the end of this follow-up period, of current symptoms and 
limitation in daily life, despite regular treatment with high dose ICS and long-
acting beta2-agonists (LABA), often associated with other drugs, therefore 
fulfitting the clinical diagnosis of severe uncontrolled asthma also according to 
the ERS/ATS document (4). 
 
Study protocol 
Cross-sectional phase  
All patients attended to our Unit on two different days, four weeks apart, 
in a stable phase of the disease (without acute asthma exacerbation in the last 
month), after withdrawal of inhaled pharmacological therapy in the last 24 hours 
during which salbutamol were allowed but not, if possible, in the last 6 hours. 
In the first day (Visit 1) they performed, in the following order: blood 
analysis for white blood cells count and serum total IgE, pre and post 
bronchodilator spirometry, measurement of exhaled nitric oxide at a flow rate of 
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50 ml/sec, collection of induced sputum to evaluate level and type of airways 
inflammation.  Patients were advised to monitor, between Visit 1 and Visit 2 
during which they continued their regular treatment, the presence of day-time 
and night-time asthma symptoms, rescue medication use, and morning and 
evening Peak Expiratory Flow (PEF) using a diary card. 
In the second day (Visit 2) patients performed methacholine challenge test 
(when possible according to baseline FEV1) and filled the Asthma Control Test 
(ACT) (34) and Asthma Control Questionnaire (ACQ) (35) to evaluate the 
control of asthma and the Asthma Quality of Life Questionnaire (AQLQ) to 
evaluate the asthma related quality of life (36).  They were sent also to ENT 
visit, in which they performed fiberoptic rhinoscopy to characterize the presence 
and the type of upper airways disease, in particular the presence of chronic 
rhinosinusitis with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP) 
and they filled the Sino-Nasal-Outcome Test 22 (SNOT-22), a validated patient-
reported measure of outcome established to delineate the presence and severity 
of sino-nasal disorders (37). In this test the patient were asked to score a list of 
22 symptoms, social and emotional consequences. Outcomes were graded as 0 
(no problem), 1 (very mild problem), 2 (mild or slight problem), 3 (moderate 
problem), 4 (severe problem), or 5 (problem as bad as it could be). The list 
included: need to blow nose, sneezing, dripping nose, cough, postnasal drip, 
dense nasal drip, ear fullness, dizziness, ear pain, facial pain/pressure, difficulty 
falling asleep, wake up at night, lack of a good night’s sleep, wake up tired, 
fatigue, reduced productivity, reduced concentration, frustrated/restless/irritable, 
sad, embarrassed, de-crease in smell and taste, nasal obstruction.  
Finally, we collected for each patient demographic data, smoking habit, 
familiar history of asthma, age of onset of asthma, anthropometric data (weight, 
height, body mass index (BMI)) for assess obesity (BMI ≥ 30), the presence of 
GER (relying on the presence of previously instrumental diagnosis or the 
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assumption of PPI for the presence of symptoms) and other important 
comorbidities. The number of exacerbations in the past 12 months and any 
hospitalization due to severe exacerbations were also recorded. Adherence to 
treatment was assessed by the Morisky Adherence scale (38), a four item 
questionnaire assessing forgetfulness, carelessness, and episodic non-adherence 
with medication; we considered low adherence two or more positive responses 
in this test. 
Longitudinal phase 
After the baseline visit, we divided the sample into three groups, based on the 
type of intervention considered as a priority for each patient: 
1. “obesity group”: patients were sent to an obesity center in our hospital and 
included in a supervised weight loss program with low-energy diet.  
2. “ENT group”: patients were sent to ENT ambulatory to improve the 
treatment of CRS and nasal polyps; 
3. “Modification of asthma treatment” group: patients without ENT or obesity 
comorbidities and with adherence to therapy were recommended to increase 
the ICS therapy (at level of 2000 mcg/day of fluticasone propionate).  
We reassessed the patients after one years with a complete visit including: pre 
and post BD spirometry, methacholine test, measure of exhaled NO, sputum and 
blood inflammatory cells, evaluation of control and quality of life scores (ACT, 
ACQ, AQLQ questionnaire) and number of exacerbations in the past year.  
We lost 23 patients for refusal to continue or for inclusion in sponsored 
pharmacological trial.  
 
Methods 
Pulmonary function tests were carried out on each patient by using the 
same equipment (Elite Series pletismography Medical Graphics, St Paul, 
	  	  
16	  
16	  
Minnesota, USA) and made according to European Respiratory Society 
recommendations (39). Bronchodilator reversibility test was performed 
measuring FEV1 before and 15-20 min after 400 mcg of salbutamol, and the 
response was evaluated according to the ERS/ATS recommendations (40). In a 
subset of subjects (having a baseline FEV1 greater than 1.5 L) methacholine 
challenge test was performed. Methacholine was delivered using a DeVilbiss 
646 jet nebulizer (DeVilbiss Healthcare, Somerset, PA, USA), as described 
previously (41). The cumulative dose of methacholine producing a 20% fall in 
FEV1 (PD20FEV1) was computed.   
  Sputum was induced according to European Respiratory Society Task 
Force recommendations (42). After measurement of baseline FEV1 and pre-
treatment with 200 µg inhaled salbutamol, hypertonic saline solution (NaCl 
4.5%) was nebulized by means of an ultrasonic nebulizer (DevIlbiss Ultraneb 
2000; DeVilbiss Healthcare, Somerset, PA, USA), with 2.8 mL/min output and 
were inhaled for three 5-min periods for up to 15 min. Every 5 min, after the 
start of nebulization, subjects were asked to rinse their mouth and throat 
carefully, to discard saliva, and to try to cough sputum into a container; FEV1 
was then measured. Nebulization was stopped after 15 min or when FEV1 fell 
by ≥20% from baseline value. Saline-induced bronchoconstriction was promptly 
relieved by short-acting β2-agonist inhalation. Sputum samples were processed 
as previously reported (43), after dilution with an equal volume of 0.1% 
dithiotreithol (Sputasol, Unipath; Basingstoke, UK). Macrophages, 
lymphocytes, neutrophils and eosinophils were expressed as a percentage of 
total inflammatory cells, excluding squamous cells. The upper limit of normal 
range for sputum eosinophils  was set at 3%, as derived from a study performed 
in normal subjects (44). 
Fractional exhaled nitric oxide (FeNO) was measured at respiratory flow 
rate of 50 using a chemioluminescent analyzer (HypAir FeNO, Medisoft, 
Belgium), according to the current guidelines (45) 
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Asthma control was evaluated according to GINA guidelines (46), taking 
in consideration day-time and nigh-time asthma symptoms, rescue medication 
use, limitations in daily life in the last 4 weeks (as derived from diary card), 
FEV1%pred, and the presence of asthma exacerbations in the last year. 
Distinction between difficult-to-treat (DT-SA) and treatment-resistant (TR-SA) 
severe asthma 
 Difficult-to-treat severe asthma (DT-SA) includes patients in which 
partial or poor response to treatment reflects the presence of factors other than 
asthma alone: poor access to medical treatment, poor adherence to medication, 
poor inhalation methods, environmental exposure such as passive smoking or 
allergen exposure, psychosocial issues (including dysfunctional breathing), and 
comorbidities. In our sample no patients have poor access to medical treatment 
and dysfunctional breathing. All subjects are been trained to correct use of 
devices. With regard to allergen exposure, no patients with history of 
occupational asthma were still exposed. In conclusion, we included in the group 
DT-SA patients currently smoking, with poor adherence to therapy or with the 
following comorbidities: CRSwNP, CRSsNP, obesity, GER, or mental disease. 
 The other patients were defined as affected by treatment-resistant (TR-
SA) severe asthma. 
 
Statistical analysis 
Due to the exploratory nature of the study, no formal sample size 
calculation was made. Data were expressed as mean ± SD or median and range 
for continuous normally or non-normally distributed variables, and as absolute 
frequencies and percentages for nominal variables. Categorical variables 
(gender, atopy, early onset asthma, control of asthma, sputum eosinophilia using 
the cut-off 3%) were compared using Chi-Square analysis. Parametric tests, 
such as the paired t-test, two-sample t-test and ANOVA, were applied for data 
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that followed or were transformed to a normal distribution (age, pre-BD FEV1, 
post-BD FEV1, PD20FEV1). Logarithmic transformation was attempted in 
order to normalize the distribution of PD20FEV1 so as to allow the use of 
parametric tests. Nonparametric tests, such as the Mann–Whitney U-test, 
Wilcoxon signed-rank test and Kruskal–Wallis test, were applied for data that 
did not follow a normal distribution (duration and age of onset of asthma, 
inflammatory markers, ACT, ACQ and AQLQ scores, PEF variability and 
number of exacerbations). Statistical analysis was carried out using SPSS 13 
(SPSS Inc., Chicago IL, USA). 
 Multivariate analysis was performed, in order to assess the major 
determinants of some markers of severity. Dependent variables were: asthma not 
controlled according GINA guidelines, post-BD FEV1 < 80% predicted, sputum 
eosinophilia percentage ≥ 3%. Independent variables were: age and duration of 
asthma (as binary variables defined with the median value for threshold), gender 
(female vs. male), smoking habit (current vs. ex-smokers or non-smokers), 
CRSwNP (yes vs. no), obesity (yes vs. no), and GERD (yes vs. no). 
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RESULTS 
 
Cross-sectional phase   
Descriptive characteristics and comparison between difficult-to-treat SA and 
treatment-resistant SA  
 The mean age of patients was 59.1 years and 65.3% were female. Only 
5.6% of the patients were current smokers and 33.3% was ex-smokers, with 
median packs-year of 10.6. Respiratory function was largely different among the 
patients: post-BD FEV1 ranged from 45% to 129% of predicted, 61.1% of 
patients have normal post-BD FEV1 (>80% of predicted). Approximately 50% 
of patients had poorly controlled asthma according GINA guidelines, despite the 
high dose of asthma therapy (high dose ICS in 93.3% of patients, medium dose 
in 6.9% of patients, long-acting beta2-agonists (LABA) in all patients, 
leukotriene receptor antagonists in 62.5%, tiotropium in 29.2%, theophylline in 
19.4%, omalizumab in 18.1% and oral corticosteroids in 15.3%). Table 1 
summarizes the characteristics of the patients divided according WHO category. 
No significant differences between these two groups were observed for 
demographic, clinical, functional and biological features of the disease. We 
found a significant difference in the omalizumab therapy, 44.4% of the patients 
with TR-SA versus 14.3% of the patients with DT-SA (p=0.03). 
 The category DT-SA is very heterogeneous, as it includes smokers, not 
adherent to therapy and with various comorbidities (Figure 1) that can affect the 
functional, inflammatory and clinical parameters in a different way. 
Furthermore, more than one comorbidity can coexist in the same patient (figure 
2a and 2b). As expected, we have observed a high prevalence of CRSwNP, 
obesity and GER, so we have separately analyzed the characteristics of asthma 
in these three groups of patients. 
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Severe asthma and CRSwNP 
 CRS comprised two different clinical and pathologic entities: CRS with 
nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP) (20). In our 
study we can observe  in patients with CRS the significant impact of the 
presence of NP on lung function and eosinophilic inflammation (Pre-BD FEV1 
in % of predicted: 71.1±17.5 in CRSwNP vs. 82.5±71.1 in CRSsNP, P=0.04; 
sputum eosinophils ≥ 3% : 90% of CRSwNP vs. 50% of CRSsNP, p=0.01; 
complete data in table E1 of the Supplementary material). In view of these 
results and the higher prevalence of CRSwNP with respect of CRSsNP, we have 
considered for our analysis only the patients with CRSwNP.   
Severe asthmatics with CRSwNP compared with all other asthmatics had 
less familiarity for asthma (percent of patients with familiarity for asthma: 16 vs. 
50, p<0.01), lower lung function (pre-BD FEV1 in % of predicted value 
71.1±17.5 vs. 80.8±17.5, p=<0.05; post-BD FEV1 in percent of predicted value: 
79.2±16.4 vs. 88.9±17.9, p<0.05), higher sputum eosinophilia (31.5 (0.4-95.6) 
vs. 8.5 (0-84.1), p<0.05; patients with sputum eosinophils ≥ 3%: 90% vs. 61.8%, 
p<0.05) and higher blood eosinophilia (eosinophils as percent of leukocytes: 6.2 
(0-30) vs. 3.8 (0.3-19.6), p<0.05). Despite this, the two groups of patients had 
similar indices of control and quality of life (table E2 in the Supplementary 
Material). Finally, we don’t find any difference in atopy, age of asthma onset, 
asthma therapy and exacerbations. Instead, as expected, we observed a greater 
use of corticosteroid therapy in the group of asthmatics with nasal polyps (88% 
vs. 63.8%, p=0.03).  
 
Severe asthma and obesity 
 Obese asthmatics had a similar functional and inflammatory data than 
non-obese, but worse asthma control  (ACT score: 16 (7-25) vs. 21 (11-25), 
p<0.05; poorly controlled according GINA guidelines: 19 (76%) vs. 18 (38.3%), 
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p<0.05) and quality of life index (AQLQ score: 4.4 (3.0-6.2) vs. 4.9 (2.7-6.9), 
p<0.05), with no-difference in atopy, age of asthma onset, familiarity for asthma 
and asthma treatment (for complete data see table E3 in the Supplementary 
Material). We can observe a trend in decrease in sputum eosinophilia in obese 
asthmatics (8.3 (0-71.2) vs. 17.4 (0-95.6), p=0.07). 
 
Severe asthma and GER 
Patients with GER compared with other patients showed similar 
demographic, functional and inflammatory characteristics (for complete data see 
table E4 in the Supplementary material), but had a worse quality of life (AQLQ: 
4.4 (2.7-6.2) vs. 5.0 (3.2-6.9), p=0.04). There was no difference in prevalence of 
obesity between the two groups. 
 
Multivariate analysis of factors contributing to poor asthma control, 
eosinophilic airway inflammation and lower lung function 
We performed multivariate analysis using the of poor control, lower lung 
function (Post-BD FEV1 < 80% of predicted) and eosinophilic phenotype 
(sputum eosinophils ≥ 3%) as dependent variables and age (> vs. < median 
value 60.5 years), gender (female vs. male), smoke (actual smokers vs. ex or not 
smokers), duration of asthma (> vs. < median value 20.5 years), obesity (Y vs. 
N), CRSwNP (Y vs. N) and GERD (Y vs. N) as independent variables. Poor 
control of asthma symptoms was associated with obesity; increase of airway 
eosinophilic inflammation was associated with CRSwNP and lower duration of 
asthma; and lower lung function was associated with longer duration of asthma, 
male gender and showed a trend for the association with CRSwNP (Table 2). 
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Longitudinal phase 
 Forty-nine patients participated to longitudinal phase of our study. We 
excluded the 5 patients with poor adherence to therapy according Morinsky 
questionnaire and we lost 18 patients for these reasons: 5 entered in sponsored 
clinical trial and 13 refused to repeat the tests included in our study.  
 
Obesity group 
We enrolled fifteen patients in the weight loss program. Among the other 
obese patients, 1 entered in sponsored clinical trial, 4 entered in the ENT group 
because had both comorbidities, 4 were lost (for refusal to repeat the tests 
included in our study) and 1 was excluded because not adherent to therapy. At 
the end of the intervention period 5 patients obtained a weight reduction 
(median weight difference from follow-up visit to baseline: -15.1 Kg, range 
from -18.2 Kg to -8.9 Kg) and 10 patients conserved or increased their weight 
(median weight difference from follow-up visit to baseline: +2.3 Kg, range from 
-2.02 Kg to +10.9 Kg).  
Table 3 show the functional and inflammatory markers, indices of asthma 
control and asthma-related quality of life and exacerbations at baseline and 
follow-up visit in patients with weight reduction (Table 3). We observed a 
significant improvement of ACQ and AQLQ scores only in the patients with 
weight reduction. We don’t observe any modifications in asthma outcome in 
patients with stable-increased weight (table E5 in the Supplementary material). 
 
ORL group 
Twenty-three patients were enrolled in the ENT program. Among the 
other patients with CRS, 2 entered in sponsored clinical trial, 5 entered in the 
obesity group because had both comorbidities and 9 were lost for refusal to 
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repeat the exams included in our study. Three patients were subjected to surgical 
treatment and the others to medical treatment of CRS. During the follow-up 
visit, ENT specialist considered improved 17 patients and unchanged-worsened 
6 patients, on the basis of clinical and rhinoscopic exams, but we did not found 
any difference in asthma outcomes in these 2 groups of patients (data not 
shown). 16 patients compiled SNOT-22 questionnaire both in the baseline and 
in the follow-up visit and on the basis of SNOT 22 questionnaire 6 patients were 
unchanged-worse and 10 patients were improved. Table 4 shown the functional 
and inflammatory markers, indices of asthma control and asthma-related quality 
of life and exacerbations at baseline and follow-up visit in patients with 
improved SNOT-22. We observed a trend in reduction of asthma exacerbations 
(p=0.057).  We don’t observe any modifications in asthma outcome in patients 
with unchanged-worse SNOT-22 (table E6 in the Supplementary material). 
 
Modification of asthma treatment group  
Among the resting 16 patients without CRS or obesity and adherent to 
therapy, 11 patients entered in a randomized study investigating the effect of 
increasing the ICS treatment at 2000 mcg of fluticasone propionate or equivalent 
on functional and inflammatory markers, indices of asthma control and asthma-
related quality of life and exacerbations. Three patients refused to repeat the 
exams included in our study and 2 patients entered in sponsored clinical trial. 
No significant differences were observed. Table E7 in the Supplementary 
material shows the results only in the five patients in the treatment group.  
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DISCUSSION 
Cross-sectional phase 
The results of the present study confirm the high prevalence of 
comorbidities in patients with severe asthma, in particular obesity, CRSwNP 
and GER, and show that control of asthma, lung function and airway 
eosinophilic inflammation are associated with different comorbidities. In 
particular obesity is associated with poor control of asthma, poor quality of life 
and lower sputum eosinophilic inflammation, CRSwNP is associated with lower 
lung function and airway and systemic eosinophilic inflammation and GER is 
associated with poor quality of life. In a multivariate analysis taking in 
consideration these comorbidities and age, gender, smoke and duration of 
asthma; obesity is the only independent factor associated with poor control (OR 
of 4.9), CRSwNP and duration of asthma are the only independent factors 
associated with airway eosinophilia (OR 16.2 and 0.1 respectively). Lower lung 
function is associated with the male gender and the longer duration of asthma 
(OR 3.9 and 5.1 respectively) and shows a trend for the association with 
CRSwNP (OR 2.9, p=0.06).  
The distinction in DT-SA and TR-SA suggested in the WHO document 
did not show significant differences between the two groups, due to the 
heterogeneity of the patients with DT-SA, but it is still important for the 
identification of the patients that require a multidisciplinary approach.  
The prevalence of GER and CRS in this asthmatic population is in line 
with previous large studies on severe asthmatics (11, 47).  The prevalence of 
obesity is variable in different studies, probably related to difference in 
epidemiologic prevalence of obesity in general population; for example, in the 
Severe Asthma Research Program cohort the prevalence of obesity was 37% in 
the total cohort of asthmatics and 44-58% in the more severe clusters (23), in a 
Dutch cohort the prevalence of obesity in severe asthmatics was 21% (24). Also 
	  	  
26	  
26	  
the prevalence of psychopathologies in severe asthmatics was higher in 
previously studies, but evaluated by specific questionnaire or psychiatric 
interview (instead in our study we considered only the intake of psychiatric 
therapy) (48,49).  
Previous studies showed the association between CRS and asthma 
(50,51), the correlation in severe asthmatics between paranasal CT scan 
abnormalities and sputum eosinophilia and pulmonary function (13), the 
association between CRSwNP and a more severe asthma phenotype (52), an 
increase of airway eosinophilic inflammation (14,15) and a lower lung function 
(15). In our sample we have observed an higher blood eosinophilia both in 
patients with CRSsNP and in those with CRSwNP, but a close association with 
sputum eosinophilia and lower lung function only for CRSwNP. This in in line 
with the concept that CRSwNP and CRSsNP should be considered two different 
clinical and pathologic entities (53), with different relation with lower airways, 
as showed also in the study of Guida et al, in which the association between 
CRS and asthma, as well airway inflammation (increased eNO), depends on the 
diagnostic classification of CRS, the type with nasal polyps being more 
significantly associated both with asthma and with increased eNO compared 
with CRSsNP  (54). The aetiology for the connection between asthma and CRS 
is multifactorial, involving nasal blockage (with lost of the filtration, 
humidification and worming function of the nose), naso-bronchial reflex,  post-
nasal drip with aspiration of inflammatory cells and/or mediators from the nose 
into the lower airways, and release of cytokine from the nose into the 
bloodstream with systemic and pulmonary effects (55). We can speculate that 
the mechanism that underlies this linking is different in the two forms of CRS: 
with systemic inflammation in both forms but greater aspiration of inflammatory 
mediator in the CRSwNP. 
Also obesity is a common comorbidity associated with difficult asthma 
and large studies have identifies an asthma phenotype characterized by obesity, 
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late onset asthma, frequent corticosteroid use and non-eosinophilic inflammation 
(7, 23). Also in our data obese patients show worse control of asthma and 
asthma-related quality of life, with a trend to lower sputum eosinophilic 
inflammation.  
Finally, in our sample of patients, the presence of GER does not seem to 
significantly impact on control of asthma, airway inflammation and lung 
function, resulting a significant difference only in asthma-related quality of life.  
Indeed, some data suggest that GERD treatment in asthmatics with symptomatic 
GER improve their quality of life and may improve asthma exacerbations (56), 
but clinical trials with anti-reflux therapy generally show little to no effect on 
asthma control (31,56). It is likely that treatment of GER results in an 
improvement in overall well-being and consequently in quality of life related to 
asthma (57). 
In view of the overlap between the comorbidities, we performed a 
multivariate analysis using the poor control, lower lung function (Post-BD 
FEV1 < 80% of predicted) and eosinophilic phenotype (sputum eosinophils 
≥3%) as dependent variable and we confirm the close association between 
CRSwNP and sputum eosinophilia and between obesity and poor control of 
asthma.  
In the multivariate analysis we have also observed that male gender and 
long duration of asthma are risk factors of lower lung function. Prospective 
studies of lung function decline in severe asthma are limited, but in a TENOR 
(The Epidemiology and Natural History of Asthma: Outcomes and Treatment 
Regimens) study analysis, persistent airflow limitation in patients with severe 
asthma was associated with older age, male gender, smoking, aspirin sensitivity, 
longer asthma duration and black ethnicity. (59) It is known then the severity of 
asthma in greater in women, however the authors of in this large study explain 
the association between male gender and lower lung function with the earlier 
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onset and greater incidence of childhood asthma in male patients while airways 
are still developing and growing, resulting in changes that predispose the 
airways toward remodelling during adulthood.  
Finally, we have observed that a long duration of asthma is negatively 
associated with airway eosinophilia. This is in line with the identification of a 
late-onset eosinophilic severe asthma in the large studies that utilized the cluster 
analysis for the identification of asthma phenotypes (6,7).   
On the contrary, in our sample of patients we don’t find an association 
between asthma comorbidities and exacerbations, while in the study of ten 
Brinke et al (59) is descripted that recurrent exacerbations in adult severe 
asthma are more frequent in patients with comorbid conditions such as severe 
sinus disease, gastro-oesophageal reflux, recurrent respiratory infections and 
obstructive sleep apnoea. This difference may be due to the exclusion of the 
patients in chronic OCS in the study of ten Brinke, to the different mean age of 
the two samples of patients e to the fact that our patients were receiving therapy 
either for GER that for CRS.  
This study differs from previous ones because we have analysed more 
comorbidities together and their impact in many asthma parameters (control of 
asthma, lung function, airway inflammations, asthma-related quality of life, 
exacerbations). Strength of our study is the careful characterization of both 
asthma and upper airway disease. A limitation is that we have performed only 
an anamnestic evaluation of GER and psychopathologies, without the use of 
instrumental or specialized confirmations.      
In conclusion, the cross-sectional phase of our study confirms the high 
prevalence of comorbidities, often coexisting, in patients with severe asthma and 
highlights their association with different asthma outcome. In particular, the 
association between obesity and poor asthma control, between CRSwNP and 
airway eosinophilia and lower lung function and between GER and lower 
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quality of life suggests the importance of the rigorous characterization of the 
asthmatic patients for direct their correct management. 
Longitudinal phase 
For the results of longitudinal phase of our study, the number of patients 
included in the various groups is too small to draw any definite conclusions. 
However, we observed that the weight loss in obese severe asthmatics could 
induce an improvement in control of asthma and asthma-related quality of life 
and an effective treatment of CRS in severe asthmatics with this upper airway 
comorbidity could determine a reduction in asthma exacerbations. An increase 
of ICS at 2000 mcg/day of fluticasone propionate does not seem to make any 
benefit in asthma outcomes. These observations are in line with what is 
described in the literature. 
As for obese asthmatics, the studies on effects of weight loss show a 
positive effect on asthma control and lung function, that seem not to be 
accompanied by remission in airway inflammation. However, only 2 studies 
have been performed in severe asthmatics, with different results. In 2010, 
Bafadhel et al examined 151 severe asthmatics in a one-year observational study 
(in which 54% of patients had a mean increase in weight of 4.9 Kg) and showed 
a significant correlation between weight loss and increased FEV1, whereas no 
significant association was found between weight change and self-reported 
asthma control and exacerbations (28). Recently, in a randomised study in obese 
severe asthmatics (33 patients), the weight loss was associated with 
improvements of asthma control, without changes in markers of airway 
inflammation or bronchial reactivity (29). Also in our small sample, we did not 
observe a change in lung function or airway inflammation. An explanation of 
these results is that obese patients may have asthma-like symptoms caused by 
changes in lung mechanics instead of being caused by asthmatic airway inflam-
mation. Another possible explanation may be that obese patients with asthma 
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represent a distinct asthma phenotype, as supported by the study of Scott et al, in 
which obese asthmatics had an increase in neutrophilic airway inflammation, 
finding that may also explain the suboptimal response to steroid-therapy often 
observed in obese asthmatics (60) 
As for CRS treatment, the poor results of our study can be attributed to 
the fact that in many patients our intervention was only a refinement of the ENT 
therapy and not a new introduction (87.2% were already taking nasal steroids 
and the ENT intervention has been the optimization of their dosage and the 
introduction of saline nasal douche and in some cases of long term macrolide), 
providing no or little further benefit, and only 3 patients were subjected to 
surgery treatment. In addiction, unlike the previous, our study was conducted 
only in patients with severe asthma, in which the respiratory disease is so 
important and complex as to make difficult to highlight small benefits.  
Finally, the increase of ICS therapy at 2000 mcg/day of fluticasone 
propionate, as expected, did not have induced any significant improvement in 
the clinical, functional and inflammatory findings. According the GINA 
guidelines, we should introduce oral corticosteroids to improve asthma control 
in these patients. Considering the adverse effects of this therapy, we have made 
an alternative attempt of increasing inhaled corticosteroid therapy, without 
significant results. It is known that most of the benefit from ICS is achieved in 
adult at relatively low doses and their increase at higher doses provides little 
further benefit. However, there is marked individual variability of 
responsiveness to ICS, so many patients can require higher doses to achieve 
therapeutic benefit. Also in this case, the small number of subjects does not 
allow to draw any definitive conclusion from this part of the study.  
In conclusion, longitudinal phase of our study, despite the small sample, 
suggests that the treatment of comorbidities in severe asthmatics can make small 
but important improvement in asthma outcome and remain a fundamental step in 
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the management of these patients, in which the good control of asthma is very 
difficult to obtain.   
GENERAL CONCLUSIONS 
 
 The data reported in the present study confirm the importance of a good 
characterization (“phenotyping”) of the patients with severe asthma. In effect, 
the evaluation of the comorbidities as potential causes of the lack of asthma 
control despite high level of pharmacologic therapy may explain the different 
characteristics of these uncontrolled patients (lack of control of symptoms, 
pulmonary function or airway inflammation) and then may lead to specific 
indication of management. Despite the exploratory characteristic of our study, 
our data confirm that targeting specific comorbidities or features of these severe 
asthmatics may lead to an improvement in asthma control. This “personalized 
pharmacologic or non pharmacologic therapy” is now the main characteristic of 
the management of patients with severe asthma. 
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LEGEND OF THE FIGURES 
 
Figure 1 Prevalence of smoke, comorbidities and poor adherence in patients 
with severe asthma 
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Figure 2 Overlap between the three most prevalent comorbidities in our sample 
of asthmatics (2a) and evidence of patients with more than one comorbidity 
(2b). 
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Table 1. Comparison between patients with TR-SA and DT-SA. 
 
TR-SA (N=9) DT-SA (N=63) 
Age, yrs 63.1±9.3 58.5±11.3 
Gender, M/F 22.2/77.8 36.5⁄63.5 
Atopy, % 7 (77.8) 41 (65.1) 
Duration of disease, yrs 11 (3-44) 22.0 (2-57) 
Age of asthma onset, yrs 45 (3-68) 39 (2-64) 
Early onset asthma, n (%) 1 (11.1) 9 (14.4) 
Best-FEV1, % of pred 91.9±16.5 84.7±18.0 
FeNO, ppb 30.3 (15.2-48) 21.3 (3.5-86.5) 
Sputum eosinophils, % 29.1 (0-82.6) 16.5 (0-95.6) 
Sputum neutrophils, % 18.2 (1.4-63.3) 30.6 (0-96.9) 
Blood eosinophils, number 185 (50-1520) 300 (0-2490) 
Blood eosinophils, % 2.0 (0.8-16.5) 4.9 (0-30) 
Total IgE, IU/mL  149.2 (36-773) 294 (8.1-3830) 
ACT 21.0 (12-24) 19 (7-25) 
ACQ 2.0 (0.8-3.1) 1.6 (0-3.7) 
AQLQ 4.9 (3.3-6.7) 4.7 (2.7-6.9) 
PEF variability 16.5 (8.3-28) 19 (3.7-47) 
GINA, not controlled, % 5 (55.6) 32 (50.8) 
Exacerbations, no./last year 1 (0-5) 1 (0-15) 
TR-SA: Treatment-Resistant Severe Asthma; DT-SA: Difficult to Treat Severe Asthma; 
FEV1: forced expiratory volume in 1 second; FeNO: fractional exhaled nitric oxide; ACT: 
Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality-of-life 
Questionnaire;  PEF:  Peak Expiratory Flow 
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Table 2 Multivariate analysis of predictors of poor control, lower lung function 
and sputum eosinophilia. 
Indipendent 
variables 
Dependent variables 
OR (95% CI) 
Poor control 
Lower lung 
function 
Sputum 
eosinophilia ≥3% 
Age  
(> vs < median 
value) 
0.7 (0.2-1.9) 0.8 (0.3-2.5) 0.2 (0.0-1.3) 
Gender  
(F vs M) 
0.87 (0.3-2.8) 0.3 (0.1-0.9)* 1.6 (0.2-12.1) 
Smoke  
(Yes vs No-Ex) 
0.4 (0-4.9) 0.3 (0.0-4.0) 0.5 (0.0-18.7) 
Duration of asthma  
(> vs < median 
value) 
1.9 (0.6-6.1) 5.1 (1.4-18.8)* 0.1 (0.01-0.5)* 
Obesity  
(Y vs N) 
4.9 (1.6-15.4)* 1.6 (0.5-4.9) 0.6 (0.1-2.8) 
CRSwNP  
(Yes vs N) 
0.9 (0.3-2.7) 2.9 (1-9.1)§ 16.2 (1.7-151.7)* 
GER 
(Yes vs N) 
1.4 (0.5-4.2) 0.5 (0.2-1.8) 0.6 (0.1-2.9) 
CRSwP: Chronic Rhinosinusitis with Nasal Polyps; GER: Gastro-Esophageal Reflux. 
*p<0.05; § p=0.06 
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Table 3 Functional and inflammatory markers and indices of control of asthma 
and quality of, at baseline and after 1 year in the 5 obese asthmatics that 
obtained weight loss.  
  Baseline visit Follow-up visit 
Weight, Kg 98 (82-111) 80.8 (73.1-95.8) 
BMI, Kg/m2 35.1 (30.8-44.5) 29.7 (27.5-38.4) 
Pre-BD FEV1, % 73.0±23.0 73.6±21.3 
Post-BD FEV1, % 80.6±26.9 84.2±18.2 
PD20FEV1, mcg (GM) 161 210 
FeNO, ppb 18.2 (15-22.5) 18 (10.5-37) 
Sputum Eos, % 4.9 (0-51.4) 3.0 (0-59.2) 
Sputum Neu, % 49.4 (19.7-61.8) 33.4 (2.1-66.4) 
Blood Eos, % 3.9 (3.9-14) 2.3 (1.8-6.9) 
ACT 15 (7-22) 19 (15-21) 
ACQ 2.7 (0.4-3.7) 1.7 (0.3-2.7)* 
AQLQ 3.4 (3.1-4.6) 5.2 (3.2-6.6)* 
Exacerbations, no./last year 2 (0-2) 2 (0-4) 
Not controlled (GINA), n(%) 5 (100) 2 (40) 
BD: bronchodilator; FEV1: forced expiratory volume in 1 second; PD20FEV1: cumulative 
dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional exhaled nitric 
oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma 
Quality-of-life Questionnaire. *p<0.05 
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Table 4 Functional and inflammatory markers and indices of control of asthma 
and quality of life, at baseline and after 1 year in the 10 asthmatics with 
improved SNOT-22. 
  Baseline visit Follow-up visit 
SNOT-22 46.2 (21-73) 20 (7-56) 
Pre-BD FEV1, % 73.0±8.7 74.1±10.8 
Post-BD FEV1, % 78.2±9.1 76.9±12.5 
PD20FEV1, mcg (GM) 949.5 353.7 
FeNO, ppb 27.7 (9-64.5) 24.7 (8.5-47) 
Sputum Eos, % 10.9 (0.6-82.8) 25 (2.5-62.9) 
Sputum Neu, % 57.3 (4.9-92.9) 45.7 (5.3-75.8) 
Blood Eos, % 9.7 (0.7-30) 5.4 (2.9-14.5) 
ACT 23 (17-24) 23 (14-24) 
ACQ 1.1 (0.6-3.3) 1.0 (0.6-3.3) 
AQLQ 4.9 (3.40-6.6) 5.4 (3.6-6.6) 
Exacerbations, no./last year 3 (0-6) 0.5 (0-4)* 
Not controlled (GINA), n(%) 3 (30) 3 (30) 
BD: bronchodilator; FEV1: forced expiratory volume in 1 second; PD20FEV1: cumulative 
dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional exhaled nitric 
oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma 
Quality-of-life Questionnaire. *p=0.057 
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SUPPLEMENTARY MATERIAL 
Table E1 Characteristics of the patients without CRS, with CRSsNP and 
CRSwNP 
 No CRS 
(N=33) 
CRSsNP 
(N=14) 
CRSwNP 
(N=25) 
Age, yrs 57.1±10.8 62.4±8.6 59.8±12.7 
Gender, M/F 24.2/75.8 50/50 40/60 
Atopy, n(%) 23 (69.7) 12 (85.7) 13 (52)§ 
Familiarity for asthma, 
n(%) 
15 (46.9) 8 (57.1) 4 (16)* 
Duration of asthma, yrs 20 (2-57) 22.2 (2-48) 25 (7-54) 
Pre-BD FEV1, % 80.1±18.2 82.5±71.1 71.1±17.5 
Post-BD FEV1, % 89.7±19.1 87.2±15.1 79.2±16.4 
PD20FEV1, mcg 321.9 819.2 872.2 
FeNO, ppb 21.5 (3.5-86) 18 (5.2-71.5) 27.5 (8.6-86.5) 
Sputum Eos, % 8.5 (0-84.1) 8.8 (0-82.6) 31.5 (0.4-95.6)§ 
Sputum Eos>3% 15 (68.2) 6 (50) 18 (90)* 
Sputum Neu, % 34.6 (0-95.3) 30.6 (0.3-83.9) 19.1 (0-96.9) 
Blood Eos, % 2.9 (0.3-16.5) 5.9 (0.7-19.6) 6.4 (0-30)* 
ACT 19.0 (7-25) 21.5 (14-25) 20 (10-24) 
ACQ 2.0 (0-3.7) 1.2 (0-2.3) 1.8 (0.6-3.3) 
AQLQ 4.6 (3.0-6.7) 4.9 (4.2-6.9) 4.6 (2.7-6.6) 
PEF variability 21 (7.7-35) 10 (3.7-30) 19 (5-47)° 
Exacerbations, n./last yr 1 (0-15) 1.5 (0-7) 1 (0-6) 
CRS: chronic rhinosinusitis; NP: nasal polyposis; BD: bronchodilator; FEV1: forced expiratory volume in 1 
second; PD20FEV1: cumulative dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional 
exhaled nitric oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality-
of-life Questionnaire. § p=0.09; ° p=0.07; * p<0.05 
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Table E2 Characteristics of severe asthmatics with CRSwNP compared with 
those without CRSwNP 
 Asthmatics with 
CRSwNP  
(N=25) 
Asthmatics without 
CRSwNP 
(N=47) 
Age, yrs 59.8±12.7 58.7±10.4 
Gender, M/F (%) 40/60 31.9/68.1 
Familiarity for asthma, n(%) 4 (16) 23 (50)§ 
Pre-BD FEV1, % 71.1±17.5 80.8±17.5* 
Post-BD FEV1, % 79.2±16.4 88.9±17.9* 
PD20FEV1, mcg 872.2 453.4 
FeNO, ppb 27.5 (8.6-86.5) 18.5 (3.5-86) 
Sputum Eos, % 31.5 (0.4-95.6) 8.5 (0-84.1)* 
Sputum Eos≥3%, % 90 61.8* 
Sputum Neu, % 19.1 (0-96.9) 31.8 (0-95.3) 
Blood Eos, % 6.2 (0-30) 3.8 (0.3-19.6)* 
ACT 20 (10-24) 19.1 (7-25) 
ACQ 1.8 (0.6-3.3) 1.4 (0-3.7) 
GINA, not controlled n(%) 12 (48) 25 (53.2) 
AQLQ 4.6 (2.7-6.6) 4.9 (3.0-6.9) 
Exacerbations, no./last year 1 (0-6) 1.5 (0-15) 
CRSwNP: chronic rhinosynusitis with nasal polyps; BD: bronchodilator; FEV1: forced expiratory volume in 1 
second; PD20FEV1: cumulative dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional 
exhaled nitric oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality-
of-life Questionnaire. * p<0.05; § p<0.01 
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Table E3 Characteristics of obese severe asthmatics compared with those 
normal-weight 
 Obese asthmatics 
(N=25) 
Not obese asthmatics 
(N=47) 
Age, yrs 60.4±9.3 58.4±12.0 
Gender, M/F (%) 24/76 40.4/59.6 
Familiarity for asthma, n(%) 8 (32) 19 (41.3) 
Pre-BD FEV1, % 76.9±22.3 77.7±15.5 
Post-BD FEV1, % 84.6±21.6 86.1±15.8 
PD20FEV1, mcg 602.0 547.5 
FeNO, ppb 18.7 (5.2-68.5) 24.9 (3.5-86.5) 
Sputum Eos, % 8.3 (0-71.2) 17.4 (0-95.6)§ 
Sputum Neu, % 48.2 (0-95.3) 18.5 (0-96.9) 
Blood Eos, % 3.9 (0.7-14) 5.6 (0-30) 
ACT 16 (7-25) 21 (11-25)* 
ACQ 2.3 (0-3.7) 1.4 (0-3.3) 
GINA not controlled, n(%) 19 (76) 18 (38.3)* 
AQLQ 4.4 (3.0-6.2) 4.9 (2.7-6.9)* 
Exacerbations, no./last year 2 (0-15) 1 (0-7) 
BD: bronchodilator; FEV1: forced expiratory volume in 1 second; PD20FEV1: cumulative 
dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional exhaled nitric 
oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma 
Quality-of-life Questionnaire. *p<0.05; § p=0.07 
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Table E4 Characteristics of asthmatics with GER compared with those without 
GER 
 Asthmatics with GER 
(N=29) 
Asthmatics without GER 
(N=43) 
Age, yrs 59.8±10.8 58.6±11.5 
Gender, M/F (%) 31/69 37.2/62.8 
Familiarity for asthma, n(%) 11 (37.9) 16 (37.2) 
Pre-BD FEV1, % 77.0±16.8 77.7±18.9 
Post-BD FEV1, % 85.7±13.4 85.5±20.5 
PD20FEV1, mcg 524.1 594.9 
FeNO, ppb 23.5 (3.5-86.0) 21.5 (5.2-86.5) 
Sputum Eos, % 11.7 (0-82.8) 21.5 (0-95.6) 
Sputum Neu, % 30.6 (0-96.9) 27.1 (0-92.9) 
Blood Eos, % 4.2 (0.3-30) 4.9 (0-23.7) 
ACT 19 (7-25) 21 (10-25) 
ACQ 2.0 (0-3.7) 1.4 (0-3.4) 
GINA not controlled, n(%) 17 (58.6) 20 (46.5) 
AQLQ 4.4 (2.7-6.2) 5.0 (3.2-6.9)* 
Exacerbations, no./last year 1 (0-15) 1 (0-12) 
GER: Gastro-Esophageal Reflux; BD: bronchodilator; FEV1: forced expiratory volume in 1 
second; PD20FEV1: cumulative dose of methacoline provoking a 20% decline in FEV1; 
FeNO: fractional exhaled nitric oxide; ACT: Asthma Control Test ACQ: Asthma Control 
Questionnaire; AQLQ: Asthma Quality-of-life Questionnaire. *p<0.05 
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Table E5 Functional and inflammatory markers and indices of control of asthma 
and quality of life, at baseline and after 1 year in the 10 obese asthmatics that 
did not obtain weight loss. 
  Baseline visit Follow-up visit 
Weight, Kg 89 (70-100) 91.3 (70-105.9) 
BMI 33.9 (30.1-44) 33.9 (29.4-41.8) 
Pre-BD FEV1, % 77.5±21.6 84.1±17.5 
Post-BD FEV1, % 85.3±19.6 88.4±16.5 
PD20FEV1, GM 523.3 Only 2 measure 
FeNO, ppb 14 (5.2-28.5) 13 (10-43.5) 
Sputum Eos, % 1.7 (0-71.2) 3.6 (0.6-16.8) 
Sputum Neu, % 28.3 (0-95.3) 48.8 (31.1-86.1) 
Blood Eos, % 3.7 (0.9-10.4) 3.2 (1.6-9.8) 
ACT 16 (12-23) 20 (8-25) 
ACQ 2.3 (0.5-3.5) 1.6 (0-3.7) 
AQLQ 4.3 (3.0-5.3) 4.2 (2.1-6.7) 
Exacerbations, no./last year 2.5 (0-15) 1 (0-3) 
GINA not controlled, n(%) 9 (90) 5 (50) 
BD: bronchodilator; FEV1: forced expiratory volume in 1 second; PD20FEV1: cumulative 
dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional exhaled nitric 
oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma 
Quality-of-life Questionnaire.  
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Table E6 Functional and inflammatory markers and indices of control of asthma 
and quality of life, at baseline and after 1 year in the 10 asthmatics with worse 
SNOT-22. 
  Baseline visit Follow-up visit 
SNOT-22 19.5 (6-37) 35.5 (17-56) 
Pre-BD FEV1, % 78.1±18.8 81.2±17.9 
Post-BD FEV1, % 83.5±20.3 87.5±18.3 
PD20FEV1, GM 514.9 80.2 
FeNO, ppb 49.5 (40.5-71.5) 35 (14-62) 
Sputum Eos, % 60.5 (29.8-95.5) 28.6 (12-42.9) 
Sputum Neu, % 6.2 (0.3-52.3) 45.5 (30.7-63.7) 
Blood Eos, % 5.3 (3.5-14.6) 4.5 (2.8-11.6) 
ACT 21.5 (19-24) 20.5 (14-23) 
ACQ 1.1 (0.1-2.3) 1.4 (0.3-3.3) 
AQLQ 4.7 (3.7-6.2) 5.3 (3.5-5.5) 
Exacerbations, no./last year 1 (0-2) 2 (0-4) 
GINA not controlled; n(%) 1 (16.7) 1 (16.7) 
BD: bronchodilator; FEV1: forced expiratory volume in 1 second; PD20FEV1: cumulative 
dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional exhaled nitric 
oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma 
Quality-of-life Questionnaire.  
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Table E7 Functional and inflammatory markers and indices of control of asthma 
and quality of life, at baseline and after 1 year in the 5 asthmatics in which we 
increased the ICS at 2000 mcg of fluticasone propionate/day 
  Baseline visit Follow-up visit 
Pre-BD FEV1, % 74.8±10.1 80.6±14.8 
Post-BD FEV1, % 91.6±5.9 86.4±17.3 
PD20FEV1, GM 511.6 602.1 
FeNO, ppb 16 (3.5-86.0) 24.7 (14-240.5) 
Sputum Eos, % 51.1 (17.3-69.1) 43.6 (1.5-84.3) 
Sputun Neu, % 31.2 (10.5-63.7) 27.3 (6.8-81.6) 
Blood Eos, % 6.7 (0.3-13.1) 7.3 (5.2-11.6) 
ACT 21 (16-22) 23 (13-24) 
ACQ 1.5 (0.8-3.2) 0.9 (0.6-2.7) 
AQLQ 4.9 (3.3-5.8) 4.7 (3.7-6.4) 
Exacerbations, no./last year 2 (0-5) 0 (0-2) 
GINA not controlled, n(%) 3 (60) 1 (20) 
BD: bronchodilator; FEV1: forced expiratory volume in 1 second; PD20FEV1: cumulative 
dose of methacoline provoking a 20% decline in FEV1; FeNO: fractional exhaled nitric 
oxide; ACT: Asthma Control Test ACQ: Asthma Control Questionnaire; AQLQ: Asthma 
Quality-of-life Questionnaire.  
 
